Provided by Tiger Fintech (Singapore) Pte. Ltd.

Edgewise Therapeutics, Inc.

14.30
-0.5500-3.70%
Post-market: 14.300.00000.00%16:10 EDT
Volume:485.38K
Turnover:6.98M
Market Cap:1.51B
PE:-9.22
High:14.86
Open:14.86
Low:14.21
Close:14.85
52wk High:38.12
52wk Low:10.60
Shares:105.35M
Float Shares:60.53M
Volume Ratio:0.82
T/O Rate:0.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5508
EPS(LYR):-1.4480
ROE:-27.41%
ROA:-19.06%
PB:2.56
PE(LYR):-9.88

Loading ...

BB Biotech AG Reports Q2 2025 Net Loss of CHF 100 Million; USD Share Price Up 10.2%, Currency Drag Impacts CHF Performance

Reuters
·
Jul 25

Truist Lowers Price Target on Edgewise Therapeutics to $46 From $50, Keeps Buy Rating

MT Newswires Live
·
Jul 07

Edgewise Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 30

Edgewise Therapeutics initiated with a Buy at H.C. Wainwright

TIPRANKS
·
Jun 30

Edgewise's Sevasemten Program Poised to Succeed in Becker Muscular Dystrophy, RBC Capital Says

MT Newswires Live
·
Jun 27

Wedbush Cuts Price Target on Edgewise Therapeutics to $35 From $40, Keeps Outperform Rating

MT Newswires Live
·
Jun 27

RBC Capital Remains a Buy on Edgewise Therapeutics (EWTX)

TIPRANKS
·
Jun 27

Edgewise Therapeutics Announces Positive Sevasemten Results

TIPRANKS
·
Jun 27

BUZZ-Edgewise Therapeutics falls after mid-stage study data found insufficient for accelerated approval

Reuters
·
Jun 27

BRIEF-Edgewise Therapeutics Reports Positive Results On Sevasemten Program

Reuters
·
Jun 26

Edgewise Therapeutics Inc. Advances Sevasemten Program with Positive FDA Feedback and Clear Path for Becker Therapy Approval

Reuters
·
Jun 26

Edgewise Therapeutics Price Target Maintained With a $48.00/Share by RBC Capital

Dow Jones
·
Jun 05

Edgewise Therapeutics to Present at Annual Goldman Sachs Global Healthcare Conference

Reuters
·
Jun 03

Treehouse Foods, GeneDx Holdings See Activist Action -- Barrons.com

Dow Jones
·
May 17

Edgewise Therapeutics Inc. to Present at RBC Capital Markets Global Healthcare Conference

Reuters
·
May 14

Wedbush Adjusts Price Target on Edgewise Therapeutics to $40 From $43, Maintains Outperform Rating

MT Newswires Live
·
May 09

Edgewise Therapeutics' Q1 Net Loss Widens; Shares Down Over 3%

MT Newswires Live
·
May 08

Edgewise Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Edgewise Therapeutics reports Q1 EPS (43c), consensus (42c)

TIPRANKS
·
May 08

BRIEF-Edgewise Therapeutics Q1 Operating Expenses USD 45.959 Million

Reuters
·
May 08